ClinicalTrials.gg
RecruitingNCT07289399Updated Dec 17, 2025

Is There a Benefit From Addition of Treadmill Walking to Diet Restriction in Psoriasis Women With PCOS?

An interventional study of exercise and diet restriction and diet restriction in Psoriasis and Polycystic Ovary Syndrome, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to female participants aged 35 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-12-17.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
35 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Psoriasis by Cairo University — 6 open to participants now, 6 under way, 1 of them phase 3. Psoriasis · Cairo University.

Planned enrollment
7th of 20
40 · median 40
Started
2025
with 1 other
No phase
13 of 22
4 open now
Registered
16th of 22
by date

Among the 22 studies in Psoriasis by Cairo University, this one is the 7th largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2025, is one of 13 with no phase, and was the 16th registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

6 of the 22 studies in Psoriasis by Cairo University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.

This study: 35 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Psoriasis by Cairo University, or all of them as a file.
02

Study summary

Women with psoriasis usually develop many complications including polysyctic ovarian syndrome (PCOS). Nowdays, diet restriction combimed with phsyical exercises may improve both problems

Read the detailed description

Forty Women with psoriasis with PCOS will be enrolled to be catogrized to Group I or group II. Group I will enroll twenty females with PCOS and Psoriasis who will apply forty minutes walking on treadmill three times per week. Also Group I will follow low calorie diet and daily metformin for 12 weeks. Group II will will enroll twenty females with PCOS and Psoriasis who will follow low calorie diet and daily metformin for 12 weeks

03

Conditions studied

  • Psoriasis
  • Polycystic Ovary Syndrome
04

Who can participate

Ages eligible
35 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obese (class I) women
  • chronic plaque psoriasis
  • polyscytic ovarian syndrome

Exclusion criteria

Exclusion Criteria:

  • cardiac dysfucntions
  • liver diseases
  • repsiratory disease
  • vascular diseases
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    group number 1

    Group I will enroll twenty females with PCOS and Psoriasis who will apply forty minutes walking on treadmill three times per week. Also Group I will follow low calorie diet and daily metformin for 12 weeks.

    Behavioral: exercise and diet restriction

  • Active comparator
    group number 2

    Group II will will enroll twenty females with PCOS and Psoriasis who will follow low calorie diet and daily metformin for 12 weeks

    Behavioral: diet restriction

Interventions

  • Behavioralexercise and diet restriction

    Group I will enroll twenty females with PCOS and Psoriasis who will apply forty minutes walking on treadmill three times per week for 12 weeks. Also Group I will follow low calorie diet and daily metformin for 12 weeks.

  • Behavioraldiet restriction

    Group II will will enroll twenty females with PCOS and Psoriasis who will follow low calorie diet and daily metformin for 12 weeks

06

What researchers measure

Primary outcomes

  1. Psoariasis area and severity index

    is an index used to express the severity of psoriasis. It combines the severity (erythema, induration and desquamation) and percentage of affected area

    Time frame: it will be measured after 12 weeks

Secondary outcomes

  1. body mass index

    it will be assessed after emptying bladder and bowel

    Time frame: It will be measured after 12 weeks

  2. waist circumference

    it will be measured at level of ambilicus

    Time frame: It will be measured after 12 weeks

  3. waist hip ratio

    it will be assessed after dividing waist circumference on hip circumference

    Time frame: It will be measured after 12 weeks

  4. testesterone

    it will be assessed in serum

    Time frame: it will be measured after 12 weeks

  5. ratio of luteinizing hormone and follicle-stimulating hormone

    it is anindicator on function of sex hormones

    Time frame: It will be measured after 12 weeks

  6. Dehydroepiandrosterone

    it will be assessed in plasma

    Time frame: It will be measured after 12 weeks

  7. Dermatology life Quality Index

    it assess impact of skin disease on quality of life

    Time frame: It will be measured after 12 weeks

  8. insuiln

    it will be assessed in plasma

    Time frame: It will be measured after 12 weeks

  9. fasting blood glucose

    it will be assessed in plasma

    Time frame: It will be measured after 12 weeks

  10. HOMA-IR

    Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) is classically considered to be a good insulin resistance (IR) index

    Time frame: It will be measured after 12 weeks

  11. triglycerides

    it will be assessed in plasma

    Time frame: It will be measured after 12 weeks

  12. total cholesterol

    it will be assessed in plasma

    Time frame: It will be measured after 12 weeks

  13. high density lipoprotein

    it will be assessed in plasma

    Time frame: It will be measured after 12 weeks

  14. low density lipoprotein

    it will be assessed in plasma

    Time frame: It will be measured after 12 weeks

  15. systolic blood pressure

    it will be assessed via manual sphygmmanometer

    Time frame: It will be measured after 12 weeks

  16. diatolic blood pressure

    it will be assessed via manual sphygmmanometer

    Time frame: It will be measured after 12 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for May 2026, 7 months after the start.

Of 115 non-industry interventional studies with no phase under Psoriasis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 7 months is below that.

Counting every sponsor, half of 134 studies reached it within 19 months; a quarter within 8 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2025
First posted
Dec 17, 2025
StartActual
Oct 10, 2025
Primary completionEst.
May 15, 2026
CompletionEst.
May 15, 2026
Last update
Dec 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07289399
Lead sponsor
Cairo University
Responsible party
Ali Mohamed Ali ismail (lecturer of physical therapy for Cardiovascular, Respiratory disorder and Geriatrics, Faculty of Physical Therapy, Cairo University, Cairo University) — Principal investigator
First posted
Dec 17, 2025
Start date
Oct 10, 2025
Primary completion
May 15, 2026 (estimated)
Completion
May 15, 2026 (estimated)
Last update
Dec 17, 2025

Study contacts

Ali MA Ismail, lecturer
Contact
ali.mohamed@pt.cu.edu.eg
01005154209
Ali mohamed, lecturer
Contact
allooka2012@gmail.com
01031321109
Ali MA Ismail, lecturer
principal investigator · Cairo University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion